Trade Shionogi & Co., Ltd. - 4507 CFD

Shionogi & Co., Ltd. Company profile

About Shionogi & Co Ltd

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Shionogi & Co Ltd revenues decreased 2% to Y219.62B. Net income applicable to common stockholders decreased 20% to Y71B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Other income decrease of 93% to Y1.74B (income), Research&Development Expenses-SGA increase of 23% to Y48.22B (expense).

Equity composition

FY'99-FY'02 WAS and FY'04 DPS were estimated. FY'05-'07 1&3Q WAS was estimated and used as O/S. FY'08 3Q WAS was estimated and used for O/S. FY'08 1Q & 3Q WAS=O/S.